Clover Health (CLOV) Gets New ‘Buy’ Call, Higher PT, Climbs 8.5%
Clover Health (CLOV) shares rose 8.53% to $4.71 after Deutsche Bank initiated coverage with a 'buy' rating and $6 price target, citing growth potential in Medicare Advantage and its technology platform. The company reported Q2 net income of $28M, up from a $10.6M loss YoY, with revenues increasing 55.6% to $743.2M. Medicare Advantage membership grew 48% to 157,309. Clover raised its net income and revenue guidance for the year. Hedge fund holdings in CLOV increased fourfold to $79.06M.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide a fresh catalyst, likely sustaining the recent price rally.
Market read
First‑time earnings and guidance disclosure for CLOV, driving an 8.5% price move and a new analyst upgrade.
What to watch
Potential regulatory scrutiny of Medicare Advantage models and competition from larger insurers.
Background
Clover Health reported a swing to $28 M net income, 55.6% revenue growth, and raised its FY guidance, prompting a Deutsche Bank upgrade.
Ticker impact
Deutsche Bank upgraded Clover Health to Buy with a $6 price target after the company posted Q2 earnings beating expectations and raised its guidance.
Further upside toward the $6 target if guidance holds.
Strong revenue growth, profitability swing, and higher guidance provide a solid catalyst for short‑term buying.
Market effects
Positive signal for the Medicare Advantage and health‑insurer sector.
Supports US healthcare stocks in the near term.
Limited to US markets; no immediate global ripple.
Counterpoint
The upgrade may be premature if upcoming conference guidance falls short of expectations.
Key entities
- analystDeutsche Bank
Issued a Buy rating and $6 price target.
- companyClover Health Investments
Health‑insurer reporting Q2 results.
